Clinical trials: Cholangitis, active
Secondary Sclerosis Cholangitis in Critically Ill Patients
Secondary Sclerosis Cholangitis Prospective
SC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. Gut microbiome composition, gut permeability, bacterial translocation, inflammation and/or genetic variants contribute to the…
- Trial name
- SSCpro (NCT03566797)
- Where
- Austria
- Volunteers
- 380 people
- Sponsor
- Medical University of Graz
Primary Biliary Cholangitis (PBC)
Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Subjects with Primary Biliary Cholangitis (PBC)
- Trial name
- NCT07104201
- Testing
- Fenofibrate
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Autoimmune Liver Disease, Liver Transplant Disorder
A Study of SIPLIZUMAB in AILD and LT Patients
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including…
- Conditions
- Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- SET-SAIL (NCT06455280)
- Testing
- Siplizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Elizabeth C. Verna
Primary Biliary Cholangitis (PBC)
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a…
- Trial name
- ELFIDENCE (NCT06016842)
- Testing
- Elafibranor
- Where
- 198 sites in United States, Argentina and 26 more
- Volunteers
- 276 people
- Sponsor
- Ipsen
Primary Sclerosing Cholangitis
Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
This pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (MTT) inpatients with primary sclerosing cholangitis (PSC).
- Trial name
- NCT06197308
- Testing
- oral vancomycin and oral amoxicillin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Minnesota
Primary Biliary Cirrhosis
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
- Trial name
- NCT03301506
- Testing
- Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule
- Where
- 109 sites in United States, Argentina and 23 more
- Volunteers
- 340 people
- Sponsor
- Gilead Sciences
Liver Cirrhosis, Hepatocellular Carcinoma (HCC)
A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions
Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis.
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Cholangitis, Sclerosing
- Trial name
- VOCAL2 (NCT06864195)
- Where
- United Kingdom
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Primary Biliary Cholangitis
Detection Program for Patients With Primary Biliary Cholangitis Lost in the System
Primary biliary cholangitis (PBC) has been considered a rare disease and its management has been limited by the lack of therapeutic alternatives.
- Trial name
- RESCAT (NCT05919433)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Hospital Mutua de Terrassa
Cholangitis, Ascending Cholangitis
Rifaximin for Prevention of Recurrent Mild-to-moderate Ascending Cholangitis After Biliary-enteric Anastomosis
This single-center prospective randomized controlled trial plans to recruit 60 adult patients with recurrent ascending cholangitis after biliary-enteric anastomosis.
- Trial name
- NCT07895433
- Testing
- Rifaximin combined with standard care, Standard Care (in control arm)
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
BPC, Non Optimal Response to UDCA
Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy
Primary biliary cholangitis (PBC) is a rare chronic, progressive, cholestatic liver disease that leads to cirrhosis and its life-threatening complications if undertreated.
- Trial name
- BEZURSO 2 (NCT06443606)
- Testing
- Bezafibrate 400 mg in addition to UDCA therapy, Bezafibrate 200 mg in addition to UDCA therapy
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Sclerosing Cholangitis
Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is a chronic progressive biliary disease that affects approximately 1200 patients in the Netherlands and around 80,000 in the Western world.
- Trial name
- CATCH-IT (NCT05462093)
- Testing
- Liver Multiscan sequences, Liver Multiscan analysis, MRCP+
- Volunteers
- 200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
- Conditions
- Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
- Trial name
- NCT07678645
- Testing
- Upadacitinib 15 MG
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RenJi Hospital
Primary Sclerosing Cholangitis
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease.
- Trial name
- NCT04685200
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cholestasis
Linerixibat Long-term Safety, and Tolerability Study
This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who…
- Trial name
- LLSAT (NCT04167358)
- Testing
- Linerixibat
- Where
- 94 sites in United States, Argentina and 15 more
- Volunteers
- 242 people
- Sponsor
- GlaxoSmithKline
Primary Sclerosing Cholangitis
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (PSC).
- Trial name
- ELASCOPE (NCT07387549)
- Testing
- Elafibranor
- Where
- 231 sites in United States, Argentina and 23 more
- Volunteers
- 350 people
- Sponsor
- Ipsen
Cholangiocarcinoma, Klatskin Tumor
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting.
- Conditions
- Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
- Trial name
- ACTICCA-2 (NCT06175845)
- Testing
- Intraductal biliary radiofrequency ablation
- Where
- 9 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Primary Sclerosing Cholangitis
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC).
- Trial name
- HAAPS (NCT05295680)
- Testing
- Hymecromone
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aparna Goel
Liver Injury, Secondary to Immune Checkpoint Inhibitors
Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Background and Study Rationale Immune checkpoint inhibitors (ICI) are a breakthrough cancer treatment that boosts the immune system to fight tumors.
- Conditions
- Liver Injury, Secondary to Immune Checkpoint Inhibitors, Cancer Patients
- Trial name
- CO-CHILI (NCT06864481)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Primary Biliary Cholangitis (PBC)
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
A phase II study to evaluate safety, tolerability and efficacy of CS0159 in patients with PBC (Primary Biliary Cholangitis).
- Trial name
- NCT05896124
- Testing
- 2mg CS0159
- Where
- 16 sites in China
- Volunteers
- 75 people
- Sponsor
- Cascade Pharmaceuticals, Inc